[Bone marrow aplasia associated to the use of ticlopidine].
We report a 58 years old male that developed a bone marrow aplasia associated to the use of ticlopidine, prescribed after coronary artery stenting. The patient developed a pneumonia as a complication. He was admitted to the Intermediate Treatment Unit, receiving wide spectrum antimicrobial therapy and a granulocyte colony stimulating factor (Neupogen(r)) with favourable response. Ticlodipine is an effective antiplatelet agent, but has serious hematological and other side effects. Its prescription requires a close follow up and search for complications.
Ruiz
Carolina
C
Facultad de Ciencias Médicas, Universidad de Santiago de Chile.
Monroy
Tatiana
T
Montaña
Nelson
N
Lora
Pilar
P
Lamich
Rubén
R
Valderrama
Alejandro
A
D001855:Bone Marrow Diseases / Q000139:chemically induced*; D000069585:Filgrastim; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use; D006801:Humans; D007958:Leukocyte Count; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects*; D010976:Platelet Count; D011994:Recombinant Proteins; D013988:Ticlopidine / Q000009:adverse effects*
D010975:Platelet Aggregation Inhibitors; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; D013988:Ticlopidine; D000069585:Filgrastim